Sign Up

Trump Administration Plan Signals Shift Toward Weight-Loss Drug Coverage For Medicare Patients

The Trump administration is preparing a pilot program that could allow some Americans on Medicare and Medicaid to access popular and costly weight-loss medications.

The plan, still in development, would permit state Medicaid programs and Medicare Part D plans to voluntarily cover GLP-1 drugs such as Novo Nordisk A/S’ (NYSE:NVO) Ozempic and Wegovy, and Eli Lilly And Co’s (NYSE:LLY) Mounjaro and Zepbound for weight management, according to internal documents reviewed by The Washington Post.

The pilot would also include Eli Lilly’s GLP-1 drug Orforglipron, pending its expected approval in 2026.

The initiative, set to launch in April 2026 for Medicaid and January 2027 for Medicare, would run through the Center for Medicare and Medicaid Innovation (CMMI).

This testing lab explores new payment models to improve care and reduce health care ...